Photo by finnnyc from unsplash
The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A,… Click to show full abstract
The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function. See related article by Gangat et al., p. 4898
Keywords:
therapy;
aurora kinase;
myelofibrosis;
kinase inhibition;
mega hit;
inhibition mega
Journal Title: Clinical Cancer Research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!